The MSLN Antibody (CAB6183) is a high-quality antibody developed for reliable detection and analysis of target proteins. This antibody, produced in rabbits, has high reactivity with human samples and has been validated for use in Western blot applications. It specifically binds to the mesothelin protein, enabling accurate detection and analysis in a variety of cell types.Mesothelin is a promising biomarker and potential target for cancer therapy, making this antibody ideal for studies in oncology and tumor biology.
This antibody is validated for use in WB, ELISA applications and has demonstrated reactivity against Human, Mouse samples.
Product Name:
MSLN Antibody
SKU:
CAB6183
Size:
20μL, 100μL
Reactivity:
Human, Mouse
Conjugate:
Unconjugated
Immunogen:
Recombinant protein (or fragment).This information is considered to be commercially sensitive.
This gene encodes a preproprotein that is proteolytically processed to generate two protein products, megakaryocyte potentiating factor and mesothelin. Megakaryocyte potentiating factor functions as a cytokine that can stimulate colony formation of bone marrow megakaryocytes. Mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may function as a cell adhesion protein. This protein is overexpressed in epithelial mesotheliomas, ovarian cancers and in specific squamous cell carcinomas. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.
Purification Method
Affinity purification
Gene ID
10232
RRID
AB_2766796
Buffer Information
Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS containing 50% glycerol, preserved with proclin300 or sodium azide, pH 7.3.
Western blot analysis of lysates from OVCAR3 cells, using (CAB6183) at 1:1000 dilution. Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) (CABS014) at 1:10000 dilution. Lysates/proteins: 25μg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (AbGn00020). Exposure time: 10s.
